Blood Sampling Strategies and Treatment Outcomes of Anticancer Drugs

Multicenter Study on Blood Sampling Strategies and Treatment Outcomes in Patients Receiving Anticancer Drugs - Exposure-response relationships of anticancer drugs in a real-world cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON61392

Enrollment

2500

Registered

2025-11-24

Start date

2026-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

No investigational product or intervention applicable. This study does not include a therapeutic intervention. No individual (dose) modifications are advised to participants based on their measurement

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients using a registered anticancer drug that is used in standard careInformed consent is given by patientAge = 18 years at time of signing ICF

Exclusion criteria

Exclusion criteria: Patient from whom it is impossible to collect blood samplesAny other circumstances that may influence the participation of the subject in a negative way

Design outcomes

Primary

Measure	Time frame
Feasibility of managing blood sample logistics both at home and across multiple hospitals throughout the Netherlands	—

Secondary

Measure	Time frame
Pharmacokinetics (Cmin, calculated Cmin, AUC)	—

Countries

Netherlands

Contacts

Public ContactN Steeghs

Antoni van Leeuwenhoek (AVL)

fase1@nki.nl020 512 9111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 10, 2026